Patient characteristics of the total population and the subgroup of patients using bDMARDs on June 1, 2016.
| RA Population, n = 827 | bDMARD Users, n = 141 | |||
|---|---|---|---|---|
| Values | n | Values | n | |
| Age, yrs, mean (SD) | 63 (14) | 827 | 58 (14) | 141 |
| Disease duration, yrs, mean (SD) | 8 (8) | 824 | 11 (9) | 141 |
| Female sex, % | 65 | 541 | 70 | 99 |
| DAS28, mean (SD) | 3.1 (1.2) | 630 | 3.3 | 3.3 (1.5) |
| RF positive, % | 57 | 392/683 | 56 | 69/123 |
| Anti-CCP positive, % | 55 | 378/684 | 63 | 78/123 |
| BMI, kg/m2, mean (SD) | 27 (10) | 432 | 26 (5) | 58 |
Anti-CCP: anticyclic citrullinated peptide antibody; bDMARD: biologic disease-modifying antirheumatic drug; DAS28: Disease Activity Score in 28 joints; RA: rheumatoid arthritis; RF: rheumatoid factor.